- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04257396
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy
Multicentre Randomized Controlled Trial Of A Carbon-Fibre Adjustable Reusable Accessory (CARA) For Supine Breast Positioning To Reduce Toxicity In Whole Breast Adjuvant Radiotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed to assess the effectiveness of utilizing the CARA positioning device for reducing the incidence and severity of acute skin reactions in the infra-mammary fold in patients undergoing WBRT. Secondary outcomes include patient reported outcomes and dose to normal body tissue and organs at risk. This is a randomized controlled trial. Participants will be randomly assigned to the following two arms:
Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cheryl Duzenli, PhD
- Phone Number: 2021 604877-6000
- Email: cduzenli@bccancer.bc.ca
Study Locations
-
-
British Columbia
-
Prince George, British Columbia, Canada
- Recruiting
- BC Cancer
-
Contact:
- Robert Olson, MD
-
Surrey, British Columbia, Canada
- Recruiting
- BC Cancer
-
Contact:
- Susan Balkwill, MD
-
Vancouver, British Columbia, Canada, V5Z4E6
- Recruiting
- BC Cancer
-
Contact:
- Cheryl Duzenli, PhD
- Phone Number: 2021 604877-6000
- Email: cduzenli@bccancer.bc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older.
- Able to provide informed consent
- ECOG performance status 0 - 2
- Stage 0-3 invasive breast cancer or DCIS scheduled to received adjuvant radiotherapy to the whole breast
- Any infra-mammary skin fold of >= 0.5 cm in the supine treatment position and/or palpable lateral breast tissue falling posterior to the mid-axilla line while in supine or treatment position.
Exclusion Criteria:
- Inability to give informed consent or comply with experimental arm of trial
- Previous RT to either breast or to the chest
- Planned boost to infra mammary area
- Use of Mepitel while on treatment
- Failure to heal surgical wound or significant post-operative wound infection
- Presence of significant connective tissue disease (e.g. systemic sclerosis, SLE)
- Known radiation hypersensitivity phenotype (e.g. ataxia telangiectasia etc.)
- Breast reconstruction
- Planned partial breast irradiation, unless the treated area includes the infra-mammary fold
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 CARA Positioning
Arm 1 patients will receive CARA breast support.
The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning.
No known risks to using CARA have been identified.
|
Breast support device having a carbon-fibre breast cradle for supine patient positioning.
|
No Intervention: Arm 2 Standard of Care
Arm 2 patients will not receive CARA breast support.
Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre.
These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD.
Published rates of MD for the control arm thus pertain to a cross section of these methods.
The control arm of this study will look at all of these methods combined.
There may be centre specific preference for the control method and stratification by centre will be done.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of moist desquamation in the infra-mammary fold
Time Frame: up to two weeks post radiotherapy
|
Presence or absence of moist desquamation
|
up to two weeks post radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of moist desquamation (MD) in the IMF
Time Frame: up to two weeks post radiotherapy
|
Scoring of patch versus confluent moist desquamation
|
up to two weeks post radiotherapy
|
NCI CTAE V 4 skin toxicity
Time Frame: up to two weeks post radiotherapy
|
overall breast skin reaction scores
|
up to two weeks post radiotherapy
|
Ipsilateral Lung V20 Gy
Time Frame: prior to first treatment, 1 week
|
Planned volume of ipsilateral lung receiving >=20 Gy
|
prior to first treatment, 1 week
|
Heart V25Gy
Time Frame: prior to first treatment, 1 week
|
Planned volume of heart receiving 25Gy for left breast patients
|
prior to first treatment, 1 week
|
V50% body and V105% body
Time Frame: prior to first treatment, 1 week
|
planned volume of body receiving >=50% and >=105% of the prescribed dose
|
prior to first treatment, 1 week
|
Dose-area predictor of moist desquamation
Time Frame: through study completion, up to 5 weeks
|
Measured dose to skin using radio-chromic film on three treatment fractions
|
through study completion, up to 5 weeks
|
Workflow
Time Frame: through study completion, up to 5 weeks
|
Measured time for treatment setup
|
through study completion, up to 5 weeks
|
Reproducibility of treatment setup
Time Frame: through study completion, up to 5 weeks
|
Shifts in patient position measured with daily and weekly imaging
|
through study completion, up to 5 weeks
|
Patient Reported Skin Toxicity
Time Frame: through study completion, up to 7 weeks
|
Questionnaire with 11 questions for patients to report pain, fatigue, skin reaction, open skin, sleep and work interruption, and comfort during treatment on 4 point scale
|
through study completion, up to 7 weeks
|
User experience with the setup technique
Time Frame: through study completion, up to 5 weeks
|
Survey with 5 questions using a 4 point scale to collect radiation therapist assessment of ease of use and overall satisfaction with the setup method
|
through study completion, up to 5 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H19-03343
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adjuvant Radiotherapy for Breast Cancer
-
Centre Paul StraussCompletedBreast Cancer Female | Adjuvant RadiotherapyFrance
-
Capital Medical UniversityRecruitingBreast Cancer | Surgery | Adjuvant RadiotherapyChina
-
Instituto Nacional de Cancer, BrazilCompletedBreast Cancer | Adjuvant RadiotherapyBrazil
-
Vejle HospitalUniversity of Southern Denmark; Danish Breast Cancer Cooperative Group; Danish...CompletedBreast Neoplasms | Shared Decision Making | Radiotherapy, AdjuvantDenmark
-
Cynthia AristeiCompletedDysphagia | Breast Cancer Female | Adjuvant RadiotherapyItaly
-
Swiss Medical Food AGiOMEDICO AGCompletedCIPN in Adjuvant Colon Cancer Patients | CIPN in Adjuvant Breast Cancer PatientsGermany
-
Fundacao ChampalimaudUnknownSBRT | Adjuvant Radiotherapy | Prostate Cancer Adenocarcinoma | Salvage Radiotherapy | IGRT | Urethral SparingPortugal
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Second Affiliated Hospital, School of Medicine,...RecruitingHER2-positive Breast Cancer | Adjuvant TherapyChina
-
Institut Claudius RegaudCompletedHormono-depending Adjuvant Breast CancerFrance
Clinical Trials on Carbon-Fibre Adjustable Reuseable Accessory (CARA)
-
British Columbia Cancer AgencyCanadian Cancer Society (CCS)Completed